Guidelines

Guidelines are key to modern health and medical practice. Their recommendations are evidence-based and cover a wide range of topics - managing specific conditions, use of medicines in different settings or services and interventions to improve health.

We are keen to publicise the efforts and outputs of all our guideline Working Groups where we can. Guidelines in Practice publicise expert content on best clinical practice to primary care health professionals. They recently used our guidelines as an example of their value in ‘Accredited guidance promotes excellence in rheumatology’. Elsewhere, they are also covered in the BSR Guideline on tocilizumab in RA and how it could help practitioners and commissioners.

Below are three tables that set out the current status of all of BSR’s guidelines. New ones are being developed whilst others that already exist may be undergoing minor or major revisions. The remainder are in current use.

NICE has accredited the process used by BSR to produce its clinical guidance. Accreditation is valid for 5 years from February 2013.


For full details on our accreditation, visit nice.org.uk/accreditation.

**NB** Due to changes OUP - the publisher of our guidelines - are making to their own website we are aware that links in the table below may break or be wrong. This is beyond our direct control but we are aware of it and OUP assure us they are working to resolve the issue so the links become stable. 30 January 2017.**

Current guidelines Produced Due for revision

BSR and BHPR Non-Biologic DMARD Guidelines


Executive summary
Full guideline

2017
NICE accredited
2020

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics


Executive summary
Full guideline

2016
NICE accredited
2019
BSR and BHPR guideline for the treatment of systemic sclerosis

Executive summary
Full guideline

2016
NICE accredited
2019
Prescribing for rheumatological conditions in pregnancy and breastfeeding.
Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteriods
Part II: analgesics and other drugs used in rheumatology practice

2016
NICE accredited
 2019
Management of Adults with ANCA associated vasculitis
BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis

Executive summary
Full guideline
2014
NICE accredited
2017
Use of IV Tocilizumab in the treatment of adults with RA

Executive summary
Full guideline
2013
NICE accredited
2017
Treatment of psoriatic arthritis with biologics

June 2016: This guideline was due for revision.  After discussion with members of the Working Group who created it, it has been decided that a review of the guideline should be postponed until 2017. Here is the explanatory Statement by Dr E MacPhie, SAGWG Chair.

Executive summary
Full guideline
Audit tool
2013
NICE accredited
2017
Management of the hot swollen joint in adults

Executive summary
Full guideline
Revision statement
2006
Renewed and accepted unchanged in 2012
2016
Management of polymyalgia rheumatica

SAGWG decided that the 2009 guideline, originally due for review in 2015, remains current. It is substantially the same as the new 2015 EULAR ACR guideline: Recommendation for the Management of Polymyalgia Rheumatica.


Executive summary
Full guideline
2009 2018


Guidelines under revision Due for publication
Safety of anti-TNF therapies in RA

Executive summary
Full guidelines
mid to late 2017
The use of Rituximab in rheumatoid arthritis

Executive summary
Full guidelines
Will become part of GL above
Management of Giant Cell Arteritis

Executive summary
Full guidelines 
2016
Management of Gout

Executive summary
Full guidelines
Q2 2017


New guidelines in development Due for publication
Management of SLE
Q2 2017
Management of Sjögren’s Syndrome Q2 2017